5 Minutes with Maria Gonzalez
20 May 2016
This International Clinical Trials Day (20th May) we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future. We've sat down with MIA's Clinical Trials Manager, Maria Gonzalez to discuss.
What does a Clinical Trials Manager do and how did you get here?
In my role I work with a team of highly dedicated and caring trial co-ordinators who are responsible for looking after our trial patients. I completed a degree in nursing at The University of Sydney and worked at Royal Prince Alfred Hospital before deciding to work in clinical trials in the hope that I may contribute to life-saving research. I have been at MIA for 6 years now.
What are clinical trials so important?
Clinical trials provide patients with access to unavailable new treatments and are also the vital step in making discoveries that will enable us to find a cure for melanoma. Clinical trials are also an opportunity for patients to receive very specialised care from clinical trial co-ordinators who are available at every step along the way to support patients and their families.
What do you find most rewarding about your work?
As a nurse I am most rewarded by making a difference in the lives of those suffering with cancer. It is a privilege to be part of a patient support network at MIA and also wonderful to share in the good news when a trial treatment is successful. Although we have made significant progress and the future is positive, it is important we keep working together to find the cure.
MIA's doctors are converging on Chicago this week along with 40,000 delegates from around the globe at the biggest oncology conference in the world.
We are pleased to announce a recent expansion to the dermatology services at Melanoma Institute Australia.
This International Clinical Trials Day we reflect on the importance of clinical trials and the people who dedicate their lives to helping melanoma patients today and in the future.
MIA has launched its first eBook Melanoma Essentials – A Concise Guide, a resource for GPs and other medical, nursing and allied professionals to help them effectively diagnose and manage cases.
Dr Scot Ebbinghaus chats to us about an exciting clinical trial at MIA and where melanoma treatment is headed in the future.
A new melanoma treatment has been listed on the PBS today, giving another option for advanced melanoma patients.
MIA's Pathology Fellow Dr Louise Jackett tells us why she's joined our fellowship program to learn from the best.
MIA doctors and patient have featured in the final episode of ABC’s ground-breaking series Keeping Australia Alive.
Specialist dermatologists at MIA are researching moles during pregnancy and we are looking for study recruits.
New research is re-writing the textbooks on what we know about melanoma by highlighting the effectiveness of radiotherapy as a treatment, reversing a long-held belief that melanoma was resistant to radiotherapy.
However, Australia's burden of melanoma will stay very high over the next 15 years unless we do more. MIA's Professor Graham Mann explains.
Thank you to everyone involved in making Melanoma March 2016 a huge success
Melanoma March 2016 has officially begun with more than 300 people marching in Rockingham and Devonport.
MIA's new CEO Carole Renouf has been in her role only a month, but is already making plans for the future of MIA.
In the wake of Susie Maroney's recent announcement that she is battling melanoma, CEO Carole Renouf's opinion piece weighs in on the critical need we have in Australia to raise awareness about melanoma.
MIA's Georgina Long has been appointed Professor and awarded a coverted prize in medial research.
Melanoma March 2016 funding will be used to initiate an ambitious new project that will support the best possible care for melanoma patients around Australia through a new data and communication platform.
New research shows long-term survival in group of advanced melanoma patients treated with BRAF inhibitors
New MIA-led research has been published in the Journal of Clinical Oncology.
Melanoma March was officially launched today with the announcement of the national research project funded by the march.
Clinical research undertaken at MIA has been pivotal in supporting the recent Therapeutic Goods Administration approval of Opdivo (nivolumab) for advanced melanoma.